3000 Background: CP-675,206 has antitumor activity in pts with metastatic melanoma. A 2-stage, 2-arm phase II trial was conducted to choose the optimal dosing regimen for pivotal clinical trial testing. Methods: Eligible pts had measurable melanoma (stage IIIc or IV) progressing on or after prior therapy with ECOG PS = 1. In stage 1, 18 pts per arm were randomized to either 10 mg/kg monthly (10 Q1M) or 15 mg/kg every 3 months (15 Q3M). If 3 or more pts in either arm had CR or PR, then 25 more pts were entered to that arm. Primary endpoint was objective tumor response, and secondary endpoints were safety and survival. Results: 89 pts received at least 1 dose (44 at 10 Q1M, 45 at 15 Q3M), with both study arms moving to stage 2. 96% of pts had stage IV disease, and 57% had elevated LDH. There were no significant differences in age, sex, stage, or baseline LDH levels between study groups. A median of 3 doses (range, 1 to 26) at 10 Q1M and 1 dose (range, 1 to 9) at 15 Q3M were administered with 100% compliance. Dose delays occurred in 30% of pts treated at 10 Q1M and 16% at 15 Q3M. 2 pts at 10 Q1M and 5 pts at 15 Q3M continued on study beyond 12 months (mo). To date, 6 pts at 10 Q1M have been discontinued due to toxicity (3 diarrhea/colitis [1 requiring colectomy], Grave’s ophthalmopathy, pancreatitis, hypersensitivity reaction) and 2 pts at 15 Q3M (colitis and pancreatitis, diarrhea) (P = 0.14). There were no toxic deaths. 15 Q3M was associated with lower incidence of grade 3 or 4 AEs (31% vs 41% at 10 Q1M; P = 0.42). Responses by investigator assessment were 1 CR and 3 PRs at 10 Q1M, and 1 CR and 2 PRs at 15 mg/kg Q3M, including responses in skin, LN, bone, liver, lung, and adrenal glands. To date, only 1 pt with PR at 10 Q1M has relapsed, and the remaining responses are ongoing (18+ to 28+ mo). Median survival is 10.3 mo at 10 Q1M and 11.0 mo at 15 Q3M (P = NS). Conclusions: The 15 mg/kg Q3M regimen was chosen for further clinical testing based on comparable antitumor efficacy and a trend to improved feasibility and safety compared with 10 mg/kg Q1M. CP-675,206 at this dose and schedule is being examined in pivotal phase II and III clinical trials for pts with melanoma, and in early phase II trials in pts with CRC and NSCLC. No significant financial relationships to disclose.